394 related articles for article (PubMed ID: 35245568)
1. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery.
Kyu Shim M; Yang S; Sun IC; Kim K
Adv Drug Deliv Rev; 2022 Apr; 183():114177. PubMed ID: 35245568
[TBL] [Abstract][Full Text] [Related]
2. Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity.
Shim MK; Yang S; Park J; Yoon JS; Kim J; Moon Y; Shim N; Jo M; Choi Y; Kim K
J Nanobiotechnology; 2022 Oct; 20(1):436. PubMed ID: 36195911
[TBL] [Abstract][Full Text] [Related]
3. Small-Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery.
Li G; Sun B; Li Y; Luo C; He Z; Sun J
Small; 2021 Dec; 17(52):e2101460. PubMed ID: 34342126
[TBL] [Abstract][Full Text] [Related]
4. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.
Gao J; Wang WQ; Pei Q; Lord MS; Yu HJ
Acta Pharmacol Sin; 2020 Jul; 41(7):986-994. PubMed ID: 32317755
[TBL] [Abstract][Full Text] [Related]
5. Laser/GSH-Activatable Oxaliplatin/Phthalocyanine-Based Coordination Polymer Nanoparticles Combining Chemophotodynamic Therapy to Improve Cancer Immunotherapy.
Huang Z; Chen Y; Zhang J; Li W; Shi M; Qiao M; Zhao X; Hu H; Chen D
ACS Appl Mater Interfaces; 2021 Aug; 13(33):39934-39948. PubMed ID: 34396771
[TBL] [Abstract][Full Text] [Related]
6. Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment.
Feng B; Zhou F; Hou B; Wang D; Wang T; Fu Y; Ma Y; Yu H; Li Y
Adv Mater; 2018 Sep; 30(38):e1803001. PubMed ID: 30063262
[TBL] [Abstract][Full Text] [Related]
7. Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy.
Shim MK; Song SK; Jeon SI; Hwang KY; Kim K
Expert Opin Drug Deliv; 2022 Jun; 19(6):641-652. PubMed ID: 35603410
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
9. Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy.
Choi J; Shim MK; Yang S; Hwang HS; Cho H; Kim J; Yun WS; Moon Y; Kim J; Yoon HY; Kim K
ACS Nano; 2021 Jul; 15(7):12086-12098. PubMed ID: 34165970
[TBL] [Abstract][Full Text] [Related]
10. A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer.
Yao D; Wang Y; Bian K; Zhang B; Wang D
Biomaterials; 2023 Jan; 292():121920. PubMed ID: 36442436
[TBL] [Abstract][Full Text] [Related]
11. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
Qi J; Jin F; Xu X; Du Y
Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
[TBL] [Abstract][Full Text] [Related]
12. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast Activation Protein-α Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy.
Sun M; Yao S; Fan L; Fang Z; Miao W; Hu Z; Wang Z
Small; 2022 Mar; 18(9):e2106296. PubMed ID: 34914185
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment-responsive spherical nucleic acid nanoparticles for enhanced chemo-immunotherapy.
Ma B; Ma Y; Deng B; Xiao P; Huang P; Wang D; Liu L
J Nanobiotechnology; 2023 May; 21(1):171. PubMed ID: 37237292
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death.
Banstola A; Poudel K; Kim JO; Jeong JH; Yook S
J Control Release; 2021 Sep; 337():505-520. PubMed ID: 34314800
[TBL] [Abstract][Full Text] [Related]
16. Prodrug-Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death.
Bai S; Yang LL; Wang Y; Zhang T; Fu L; Yang S; Wan S; Wang S; Jia D; Li B; Xue P; Kang Y; Sun ZJ; Xu Z
Small; 2020 May; 16(19):e2000214. PubMed ID: 32309900
[TBL] [Abstract][Full Text] [Related]
17. Quantitative and high drug loading of self-assembled prodrug with defined molecular structures for effective cancer therapy.
Tang J; Zeng Z; Yan J; Chen C; Liu J; Feng X
J Control Release; 2019 Aug; 307():90-97. PubMed ID: 31185233
[TBL] [Abstract][Full Text] [Related]
18. Carrier-Free Nanomedicine for Cancer Immunotherapy.
Fu Y; Bian X; Li P; Huang Y; Li C
J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
[TBL] [Abstract][Full Text] [Related]
19. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
20. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.
Zhou L; Zhang P; Wang H; Wang D; Li Y
Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]